Drug intelligence / Profile preview

JW0104

Development stage: Phase 3
Lead developer: JW Pharmaceutical
Modality: Small Molecules
Administration: Oral (inferred From Typical Administration Route For Small Molecules Treating These Indications; Not Explicitly Stated)

Overview

JW0104 is a small molecule drug under development by JW Pharmaceutical for the treatment of cardiovascular and metabolic diseases, specifically targeting dyslipidemia and hypertension. It is being evaluated both as a monotherapy and in combination with other agents (such as C2402) in clinical trials. The precise mechanism of action has not been disclosed in public sources, but its therapeutic focus suggests it may act on pathways relevant to lipid metabolism or blood pressure regulation. As of March 2025, JW0104 has reached Phase 3 clinical trials in South Korea for patients with hypertension and dyslipidemia[2][7].

Beyond the preview

Go deeper on JW0104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JW0104.

Explore the full profile